Tag:

Takeda

Latest Headlines

Latest Headlines

Report: Takeda's dengue jab will be nipping at Sanofi's heels by 2020

The dengue vaccine market may not exist yet, but once it does, it's in for a big growth spurt within the next 6 years, a recent report says. And while market watchers expect Sanofi's candidate to lead the pack, by the time 2020 rolls around, Takeda could be right behind it in the battle for market share.

Takeda preps for 'stringent' R&D as a new boss takes the reins

Christophe Weber, Takeda's anointed next CEO, sees a brighter future through specialization for the Japanese drugmaker, promising to focus only on therapeutic areas where it can lead, leaving behind losing programs.

Takeda COO Weber's reset plans include acquisitions, market expansion

Takeda's board swept aside concerns over having the company run by a non-Japanese executive, setting up Frenchman Christophe Weber to carry out the plans he believes are needed to turn around the faltering drugmaker.

Takeda's chief-in-waiting sees big M&A in the drugmaker's future

Christophe Weber is next in line for the throne at Takeda, and the former GlaxoSmithKline exec has a mind to grow the Japanese pharma through dealmaking, hoping to refill the in-transition company's pipeline and expand in emerging markets.

Ex-Takeda execs bemoan reign of 'foreigners'

Takeda, Japan's largest drugmaker, has gone through a series of reorganizations in its efforts to take a bigger share of the global market, a process that has included recruiting leadership outside of its native country. That's not sitting very well with some former executives.

Takeda taken to task for hiring so many 'foreigners'

CEO Yasuchika Hasegawa's efforts to make Takeda a globally focused company with more international sales has always drawn attention, but the idea that the Japanese company could be run by a "foreigner" has a group of former executives angry and they are letting the board know it.

Takeda dumps its top cancer contender after a late-stage struggle

Takeda is walking away from orteronel, its most advanced oncology candidate, after the prostate cancer treatment failed to significantly improve overall survival in two studies, a setback for the company's in-transition Millennium unit.

UPDATED: Orexigen's weight-loss med sets up Takeda vs. Eisai marketing showdown--eventually

Orexigen Therapeutics is on the verge of FDA approval for its obesity drug, after several long years of delay and frustration. But despite its late-to-the-party status--it's the third weight-loss pill in a new generation of treatments--it may end up winning the popularity contest.

Orexigen obesity med faces uphill fight--and that's if it's approved

If Orexigen wins FDA approval for its new weight loss drug, how will it and its pharma partner Takeda take on the obesity market?

Can Orexigen and its partner Takeda escape the weight-drug jinx?

If Orexigen wins FDA approval for its weight loss drug NB32 (which used to be called Contrave) by tomorrow's long-awaited PDUFA date--and the odds are in its favor--look for the biotech and its pharma partner Takeda to barrel into a huge obesity market that has provided a chilly reception for a pair of rivals.